文献速递乳房整形与再造美容整形

乳房假体是否诱导乳腺癌免疫监视?假体置入后乳腺癌抗原抗体反应分析

Can Breast Implants Induce Breast Cancer Immunosurveillance? An Analysis of Antibody Response to Breast Cancer Antigen following Implant Placement.
PubMed 文献 · Plast Reconstr Surg · 2021-01-01

该研究比较长期乳房假体携带者与假体初治女性对乳腺癌抗原的抗体反应,并追踪9例隆乳术前术后变化。长期假体携带者对 mammaglobin-A 和 mucin-1 抗体反应更高,置入后1个月亦显著升高,首次提供假体相关乳腺癌抗原免疫反应证据。

要点

  • 长期乳房假体携带者对 mammaglobin-A 和 mucin-1 抗体反应高于假体初治女性。
  • 隆乳术后1个月对 mammaglobin-A 和 mucin-1 抗体反应显著升高。
  • 对其他乳腺癌抗原及破伤风抗体反应无差异,证据等级为治疗性V级。

核心结论

  • 长期乳房假体携带者对 mammaglobin-A 和 mucin-1 的抗体识别高于假体初治女性。
  • 该研究首次提供假体相关乳腺癌抗原免疫反应的证据。

研究设计与样本

  • 研究纳入104名健康女性,其中36名(34.6%)为长期乳房假体携带者,68名(65.4%)为假体初治女性。
  • 采用酶联免疫吸附试验检测乳腺癌抗原抗体反应,组间比较用非配对t检验。
  • 假体初治队列中9名女性接受隆乳手术,术前术后抗体反应用配对t检验比较。

主要发现

  • 长期假体携带者较假体初治女性对 mammaglobin-A 抗体反应更高(450 nm光密度0.33 vs 0.22;p=0.003)。
  • 长期假体携带者较假体初治女性对 mucin-1 抗体反应更高(450 nm光密度0.42 vs 0.34;p=0.02)。
  • 对 BRCA2、CEA、HER2 或破伤风的抗体反应无差异。
  • 9名女性术后1个月对 mammaglobin-A 抗体反应显著升高(平均差值0.13;p=0.0002)。
  • 9名女性术后1个月对 mucin-1 抗体反应显著升高(平均差值0.08;p=0.02)。

临床怎么用

  • 假体置入后可能诱导针对 mammaglobin-A 和 mucin-1 的抗体反应,临床解读乳腺癌风险时需考虑此免疫监视假说。
  • 该证据等级为治疗性V级,尚不能据此改变现有乳房假体临床管理或乳腺癌筛查策略。

局限性

  • 证据等级为治疗性V级,研究结论需更大样本和更长随访验证。
  • 纵向术前术后分析仅纳入9名女性,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Women with cosmetic breast implants have significantly lower rates of subsequent breast cancer than the general population (relative risk, 0.63; 95 percent CI, 0.56 to 0.71). The authors hypothesize that breast implant-induced local inflammation stimulates immunosurveillance recognition of breast tumor antigen. METHODS: Sera were collected from two cohorts of healthy women: women with long-term breast implants (i.e., breast implants for >6 months) and breast implant-naive women. Antibody responses to breast tumor antigens were tested by enzyme-linked immunosorbent assay and compared between cohorts by unpaired t test. Of the implant-naive cohort, nine women underwent breast augmentation, and antibody responses before and after implant placement were compared by paired t test. RESULTS: Sera were collected from 104 women: 36 (34.6 percent) long-term breast implants and 68 (65.4 percent) implant-naive women. Women with long-term breast implants had higher antibody responses than implant-naive women to mammaglobin-A (optical density at 450 nm, 0.33 versus 0.22; p = 0.003) and mucin-1 (optical density at 450 nm, 0.42 versus 0.34; p = 0.02). There was no difference in antibody responses to breast cancer susceptibility gene 2, carcinoembryonic antigen, human epidermal growth factor receptor-2, or tetanus. Nine women with longitudinal samples preoperatively and 1 month postoperatively demonstrated significantly elevated antibody responses following implant placement to mammaglobin-A (mean difference, 0.13; p = 0.0002) and mucin-1 (mean difference 0.08; p = 0.02). There was no difference in postimplant responses to other breast tumor antigens, or tetanus. CONCLUSIONS: Women with long-term breast implants have higher antibody recognition of mammaglobin-A and mucin-1. This study provides the first evidence of implant-related immune responses to breast cancer antigens. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, V.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Fracol M, Shah N, Dolivo D, et al. Can Breast Implants Induce Breast Cancer Immunosurveillance? An Analysis of Antibody Response to Breast Cancer Antigen following Implant Placement. Plast Reconstr Surg. 2021. PMID: 34398081. doi:10.1097/PRS.0000000000008165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。